Worth to buy. Wait for it to g-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

JiaminFeng
2021-06-01

Worth to buy. Wait for it to grow

Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

Even a modest investment in these unstoppable stocks could reap huge rewards over the next decade.

Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":119968549,"tweetId":"119968549","gmtCreate":1622513938581,"gmtModify":1704185409193,"author":{"id":3584954263002423,"idStr":"3584954263002423","authorId":3584954263002423,"authorIdStr":"3584954263002423","name":"JiaminFeng","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Worth to buy. Wait for it to grow</p></body></html>","htmlText":"<html><head></head><body><p>Worth to buy. Wait for it to grow</p></body></html>","text":"Worth to buy. Wait for it to grow","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/119968549","repostId":2139304437,"repostType":4,"repost":{"id":"2139304437","kind":"highlight","pubTimestamp":1622513653,"share":"https://www.laohu8.com/m/news/2139304437?lang=&edition=full","pubTime":"2021-06-01 10:14","market":"us","language":"en","title":"Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2139304437","media":"Motley Fool","summary":"Even a modest investment in these unstoppable stocks could reap huge rewards over the next decade.","content":"<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad <a href=\"https://laohu8.com/S/AONE\">one</a>.</p>\n<p>Here are two low-priced stocks that long-term investors should consider scooping up right now.</p>\n<p><img src=\"https://static.tigerbbs.com/ab4cdcd429fc79807e5230a73da31639\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h2>1. Jushi Holdings</h2>\n<p>Trading for less than $6 per share at the time of this writing, <b>Jushi Holdings</b> (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.</p>\n<p>2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.</p>\n<p>Jushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.</p>\n<p>The company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of <a href=\"https://laohu8.com/S/AONE.U\">one</a> of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.</p>\n<p>As Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.</p>\n<h2>2. <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></h2>\n<p><b>Pfizer</b> (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, <b>BioNTech </b>-- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.</p>\n<p>Pfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.</p>\n<p>During the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.</p>\n<p>In addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.</p>\n<p>Pfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHave $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 10:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISBC":"投资者银行"},"source_url":"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2139304437","content_text":"There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad one.\nHere are two low-priced stocks that long-term investors should consider scooping up right now.\n\nImage source: Getty Images.\n1. Jushi Holdings\nTrading for less than $6 per share at the time of this writing, Jushi Holdings (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.\n2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.\nJushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.\nThe company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of one of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.\nAs Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.\n2. Pfizer\nPfizer (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, BioNTech -- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.\nPfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.\nDuring the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.\nIn addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.\nPfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":26,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}